Feng Chi Biotech Corp.
Feng Chi Biotech Corp. engages in the wholesale and retail of medical equipment and precision instruments and biotechnology services in Taiwan and internationally. The company provides preimplantation genetic testing, prenatal testing, precision medicine, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. It also distributes various geneti… Read more
Feng Chi Biotech Corp. (6744) - Net Assets
Latest net assets as of June 2025: NT$233.29 Million TWD
Based on the latest financial reports, Feng Chi Biotech Corp. (6744) has net assets worth NT$233.29 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$305.31 Million) and total liabilities (NT$72.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$233.29 Million |
| % of Total Assets | 76.41% |
| Annual Growth Rate | 2.35% |
| 5-Year Change | 6.57% |
| 10-Year Change | N/A |
| Growth Volatility | 1.66 |
Feng Chi Biotech Corp. - Net Assets Trend (2019–2024)
This chart illustrates how Feng Chi Biotech Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Feng Chi Biotech Corp. (2019–2024)
The table below shows the annual net assets of Feng Chi Biotech Corp. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$239.88 Million | +0.79% |
| 2023-12-31 | NT$238.00 Million | +0.90% |
| 2022-12-31 | NT$235.87 Million | +2.33% |
| 2021-12-31 | NT$230.51 Million | +2.41% |
| 2020-12-31 | NT$225.08 Million | +5.40% |
| 2019-12-31 | NT$213.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Feng Chi Biotech Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 15.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$34.04 Million | 14.19% |
| Common Stock | NT$154.00 Million | 64.20% |
| Other Comprehensive Income | NT$21.78 Million | 9.08% |
| Other Components | NT$30.05 Million | 12.53% |
| Total Equity | NT$239.88 Million | 100.00% |
Feng Chi Biotech Corp. Competitors by Market Cap
The table below lists competitors of Feng Chi Biotech Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WANdisco plc
PINK:WANSF
|
$2.50 Million |
|
Transition Metals Corp
PINK:TNTMF
|
$2.50 Million |
|
TERADYNE
MU:TEY
|
$2.50 Million |
|
Accuracy Shipping Limited
NSE:ACCURACY
|
$2.50 Million |
|
TJGC Group Limited
NASDAQ:TJGC
|
$2.50 Million |
|
Lenox Pasifik Investama Tbk PT
JK:LPPS
|
$2.50 Million |
|
Mec Resources Ltd
AU:MMR
|
$2.50 Million |
|
Chaoprayamahanakorn Public Company Limited
BK:CMC
|
$2.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Feng Chi Biotech Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 237,998,000 to 239,879,000, a change of 1,881,000 (0.8%).
- Net income of 16,594,000 contributed positively to equity growth.
- Dividend payments of 16,170,000 reduced retained earnings.
- Other comprehensive income increased equity by 3,736,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$16.59 Million | +6.92% |
| Dividends Paid | NT$16.17 Million | -6.74% |
| Other Comprehensive Income | NT$3.74 Million | +1.56% |
| Other Changes | NT$-2.28 Million | -0.95% |
| Total Change | NT$- | 0.79% |
Book Value vs Market Value Analysis
This analysis compares Feng Chi Biotech Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.03x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$14.26 | NT$16.00 | x |
| 2020-12-31 | NT$14.57 | NT$16.00 | x |
| 2021-12-31 | NT$14.91 | NT$16.00 | x |
| 2022-12-31 | NT$15.33 | NT$16.00 | x |
| 2023-12-31 | NT$15.40 | NT$16.00 | x |
| 2024-12-31 | NT$15.52 | NT$16.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Feng Chi Biotech Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.92%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.70%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.25x
- Recent ROE (6.92%) is below the historical average (9.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 8.13% | 9.96% | 0.65x | 1.25x | NT$-4.00 Million |
| 2020 | 11.28% | 14.19% | 0.63x | 1.26x | NT$2.88 Million |
| 2021 | 10.04% | 12.67% | 0.64x | 1.24x | NT$84.30K |
| 2022 | 10.44% | 12.72% | 0.63x | 1.31x | NT$1.03 Million |
| 2023 | 9.58% | 12.62% | 0.60x | 1.26x | NT$-1.01 Million |
| 2024 | 6.92% | 9.70% | 0.57x | 1.25x | NT$-7.39 Million |
Industry Comparison
This section compares Feng Chi Biotech Corp.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Feng Chi Biotech Corp. (6744) | NT$233.29 Million | 8.13% | 0.31x | $2.50 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |